In addition to a potentially effective treatment for humans with HIV, the combination also shows potential to treat cats with leukemia.
A University of Minnesota research team featuring researchers from the Institute for Molecular Virology, School of Dentistry and Center for Drug Design has developed a new delivery system for a combination of two FDA approved drugs that may serve as an effective treatment for the human immunodeficiency virus (HIV).
The discovery, which allows for a combination of decitabine and gemcitabine to be delivered in pill form, marks a major step forward in patient feasibility for the drugs, which previously had been available solely via injection or intravenous therapy (IV).
The study, coauthored by Christine Clouser, Ph.D., Laurent Bonnac, Ph.D., Louis Mansky, Ph.D., and Steven Patterson, Ph.D., can be found “online first” in the journal Antiviral Chemistry & Chemotherapy.
“If you have a condition that requires you to take a medication everyday, as many patients with HIV do, you wouldn’t want to have to take that medication via daily injection,” said Steven Patterson, Ph.D., professor at the Center for Drug Design at the University of Minnesota. “This finding is a big step in demonstrating this treatment could be taken as a pill, similar to other HIV drugs, and is suitable for eventual clinical translation.”
University of Minnesota researchers first announced decitabine and gemcitabine could potentially combine to treat HIV in research published in August 2010. The drug combination was shown to work by lethal mutagenesis that could obliterate HIV by causing the virus to mutate to a point where it was no longer infectious. For some patients, HIV’s ability to quickly mutate and evolve can result in drug resistance. For patients who have developed resistance to currently available HIV treatments, the decitabine-gemcitabine drug combination could prove an effective alternative and secondary line of defense.
In addition to a potentially effective treatment for humans with HIV, the combination also shows potential to treat cats with leukemia.
The Latest Bing News on:
Decitabine and gemcitabine
- Side Effectson April 16, 2024 at 4:01 am
Tell your doctor if you are pregnant or plan to become pregnant. You should not become pregnant while using gemcitabine. Gemcitabine may harm an unborn baby. Your doctor should order a pregnancy ...
- Improving Cancer Care: The Role of Oral Hypomethylating Agents and Educationon April 14, 2024 at 5:00 pm
At present, patients have 2 approved options for HMAs. IV decitabine (Dacogen; MGI Pharma) and subcutaneous or IV azacitidine (Vidaza; Bristol Myers Squibb) are approved to treat MDS in the US.
- Myelodysplastic Syndromeson April 10, 2024 at 5:00 pm
The authors concluded that the data support consideration of the oral regimen of decitabine and cedazuridine to reduce the treatment burden associated with intraveous or subcutaneous ...
- Weekly Gemcitabine and Trastuzumab in the Treatment of Patients with HER2-overexpressing Metastatic Breast Canceron April 7, 2024 at 5:00 pm
Background: The use of trastuzumab in combination with either a taxane or vinorelbine has improved the efficacy of treatment for women with HER2-positive (HER+) breast cancer. We investigated the ...
- Bio-Path Holdings Provides 2024 Clinical and Operational Updateon April 2, 2024 at 12:00 am
The first two cohorts are treating patients with the triple combination of prexigebersen, decitabine and venetoclax ... to be opened in combination with gemcitabine in Stage 4 pancreatic cancer ...
- 'One-two punch' of epigenetic cancer drugs could knock out colorectal cancer cellson April 1, 2024 at 8:20 am
The researchers used a type of decitabine commercialized as Dacogen by Otsuka; tazemetostat is commercialized by Ipsen as Tazverik. Neither company was involved in the study. While agents in both ...
- What Is Decitabine And Common Side Effectson March 21, 2024 at 8:55 am
Decitabine is used in the treatment of type of blood cancer called acute myeloid leukaemia (AML). It is also used to treat patients with myelodysplastic syndrome (MDS). It may be used to treat ...
- Page settingson January 16, 2024 at 1:11 pm
Gemcitabine is used to treat certain types of cancer (including breast, lung, ovarian, pancreatic). Cisplatin is used to treat various types of cancer. Paclitaxel is used to treat various types of ...
- Gemcitabine remains the standard of care for pancreatic canceron March 30, 2023 at 5:48 pm
Pancreatic cancer is the fourth leading cause of cancer death in the US, with over 35,000 deaths reported in 2009. 1 In 1997, gemcitabine became the standard of care for advanced disease and since ...
- Bio-Path Holdings Announces First Patient Dosed in Amended Stage 2 of the Phase 2 Clinical Trial Evaluating Prexigebersen in Acute Myeloid Leukemiaon August 12, 2020 at 5:00 pm
Despite the superior combination treatment results with LDAC, the new drug decitabine was favored by oncologists. As a result, Stage 2 of the Phase 2 trial in AML dropped the combination treatment ...
The Latest Google Headlines on:
Decitabine and gemcitabine
[google_news title=”” keyword=”Decitabine and gemcitabine” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]
The Latest Bing News on:
HIV
- We have made unthinkable progress in the fight against HIV/AIDS. Where do we go from here?on April 22, 2024 at 9:00 am
Over time, HIV mutated and began to resist AZT. By 1992, AIDS had become the number one cause of death for men ages 25 to 44. It became evident that scientists and experts had to go back to the drawing board to find out how to better combat this stronger strain of the virus.
- 32 years ago, Philly began using syringe exchanges to fight AIDS. With funding now in doubt, experts fear an HIV surgeon April 19, 2024 at 10:30 am
Prevention Point and other organizations have helped prevent infections by offering drug users clean needles for free, studies show. Mayor Cherelle Parker plans to pull the city funding.
The Latest Google Headlines on:
HIV
[google_news title=”” keyword=”HIV” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]